secwatch.observer — SEC 8-K summary
======================================

Issuer:     PARDES BIOSCIENCES, INC. (—)
CIK:        0001822711
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0000950170-23-011474
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 2.05, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pardes suspends pomotrelvir after Phase 2 miss; cuts 85% workforce; explores strategic alternatives
--------------------------------------------------------------------------------

- Phase 2 trial failed primary endpoint: 70% pomotrelvir vs 63% placebo undetectable virus at day 3 (p=0.57).
- Company suspends further clinical development of pomotrelvir.
- Board initiates review of strategic alternatives including acquisition or merger.
- Workforce reduced ~85% with estimated $5.7M cash restructuring costs in Q2 2023.
- Preliminary cash, equivalents and short-term investments ~$172.4M as of Mar 31, 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1822711/000095017023011474/0000950170-23-011474-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1822711/000095017023011474/prds-20230331.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-011474

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer